RCKT (Rocket Pharmaceuticals) GF Score: 30/100 (As of Jul. 04, 2026) — 21% Below Median


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals GF Score?

Rocket Pharmaceuticals RCKT +9.25% 30 GF Score is 30 as of Jul. 04, 2026, which is 21% below its 10-year median of 38.00. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

Rocket Pharmaceuticals has the GF Score of 30, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Rocket Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Rocket Pharmaceuticals  (NAS:RCKT) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Rocket Pharmaceuticals GF Score Related Terms

RCKT vs TENX, DMAC, AVIR: GF Score Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rocket Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's GF Score falls into.


RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 30 mean?
Rocket Pharmaceuticals (RCKT) has a GF Score of 30 as of Jul. 04, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Rocket Pharmaceuticals and its competitors. This is 21% below median its historical median of 38.00. Over the past decade, Rocket Pharmaceuticals' GF Score has ranged from 16.00 to 44.00.
Is Rocket Pharmaceuticals' GF Score too high?
Rocket Pharmaceuticals' current GF Score of 30 is 21% below median its 10-year median of 38.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 44.00. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' GF Score compare to TENX and DMAC?
Rocket Pharmaceuticals' GF Score of 30 can be compared against companies in the Biotechnology industry. Historically, Rocket Pharmaceuticals' own GF Score has ranged from 16.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current GF Score is 30, which is 21% below median its own 10-year median of 38.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current GF Score of 30. The current GF Score is 30, which is 21% below median its 10-year median of 38.00. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current GF Score is 30 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price